Intrinsiqq
Processa Pharmaceuticals Inc. logo

Processa Pharmaceuticals Inc.

PCSA

Compare

Valuation & Multiples

Based on TTM earnings · Diluted shares

Market Cap$5M
EPS$1.00
P/E1.93
P/FCF-0.45
EV/EBITDA-0.40
FCF Yield–
Div. Yield–
Net Debt/FCF0.0x
Processa Pharmaceuticals Inc. intrinsic value
52-Week Range
$1.35$3.92

Profitability & Returns

Revenue

N/A

Net Income (TTM)

-$13M

▼ -14.5% YoY

Op. Margin

–

ROIC

-291.23%

▼ -25.2pp YoY

Cash Flow & Balance Sheet

FCF (TTM)

-$12M

▼ -1.2% YoY

Op. Cash Flow (TTM)

-$12M

▼ -1.2% YoY

Net Debt

-$196K

Net Cash Position

Cash & Equiv.

$196K

Continue Research

Peers

Pharmaceutical Preparations · Pick stocks to compare with PCSA

CompareIntrinsic value
PTIXProtagenic Therapeutics, Inc.
$0.54-14.29%20
ABBVAbbVie Inc.
$291.31+1.07%49
SKVISkinvisible Inc.
$0.18+15.24%0
SILOSilo Pharma Inc.
$1.33+3.10%10
CAMPCamp4 Therapeutics Corp.
$4.06+9.14%40
RANIRani Therapeutics Holdings Inc.
$0.55+6.01%10
HYPDHyperion DeFi, Inc.
$2.49-2.73%25
SERSerina Therapeutics Inc.
$1.38-16.36%40

Processa Pharmaceuticals (PCSA) in three numbers

Quality score
20/100
Best check: net debt, -$196325. Weakest: return on capital, -291.2%.
Quality
Dividend
None
Last paid in 2015, nothing since.
Dividends
P/E
1.93
Price to free cash flow -0.45.
Financials

Questions about Processa Pharmaceuticals

Is Processa Pharmaceuticals (PCSA) overvalued?

Processa Pharmaceuticals trades at 1.93 times earnings. Intrinsiqq's fair value calculator has no opening value for PCSA, so weigh those multiples against the company's own history and the peers above. See how to tell if a stock is overvalued.

Is Processa Pharmaceuticals a high-quality business?

Processa Pharmaceuticals scores 20 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 5 checks computed from SEC filings. Its best check is net debt at -$196325, and its weakest is return on capital at -291.2%. The Quality tab shows every check against its target.

Does Processa Pharmaceuticals (PCSA) pay a dividend?

No. Processa Pharmaceuticals (PCSA) does not currently pay a dividend. The last payment in our data was in 2015, and nothing has been paid since. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.

Source: 10-Q filed 7 Aug 2026 (period ending 30 Jun 2026), SEC. Price: last close 6 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.

Spot a number that looks wrong? Check it in PCSA's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing PCSA

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

SectorsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.